Meningococcal Disease, Meningococcal Meningitis
Conditions
Keywords
Meningococcal disease, vaccines, adolescents, prevention, Meningitis
Brief summary
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
Interventions
BIOLOGICALMeningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine
The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
BIOLOGICALTdap
Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
Sponsors
Novartis Vaccines
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
11 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
Individuals eligible to be enrolled into this study were male or female who completed study V102\_02 (primary study), and: 1. who were 11 to 18 years at the time of enrollment in primary study; 2. who had given their written consent at the time of enrollment; 3. who were available for all the visits scheduled in the study (ie, not planning to leave the area before the end of the study period); 4. who were in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
Exclusion criteria
1. History of any meningococcal vaccine administration; 2. Current or previous, confirmed or suspected disease caused by N meningitidis; 3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N meningitidis infection within 60 days of enrollment; 4. Significant acute or chronic infection within the previous 7 days or fever (defined as temperature \>38°C) within the previous 3 days; 5. Antibiotics within 7 days prior to enrollment or blood draw; 6. Pregnancy or nursing (breastfeeding) mothers; 7. Females of childbearing age who had not used or did not plan to use acceptable birth control measures, for the duration of the study. Oral, injected or implanted hormonal contraceptive, barrier methods (condom or diaphragm with spermicide); intrauterine device or sexual abstinence was considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods at least two months prior to study entry; 8. Any serious chronic or progressive disease (eg, neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, human immunodeficiency virus infection or acquired immunodeficiency syndrome, blood dyscrasias, bleeding diathesis, signs of cardiac or renal failure or severe malnutrition). 9. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, including use of corticosteroids in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids or immunostimulants within the previous 60 days. Use of topical corticosteroids administered during the study in limited areas (ie, eczema on knees or face or elbows) of the body was allowed; 10. Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days; 11. History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component; 12. Individuals who received any other vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study or who were planning to receive any vaccine within 4 weeks from the study vaccines. 13. Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or had intent to participate in another clinical study at any time during the conduct of this study. 14. Individuals who were part of study personnel or close family members conducting this study. 15. Individuals with medical history or any illness that, in the opinion of the investigator, might interfere with the results of the study or posed additional risk to the subjects due to participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 6 and month 7 | Antibody response was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥1:8 and associated 95% CI, directed against to N meningitidis serogroups A, C, W, and Y at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7). |
| Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 6 and month 7 | Antibody response was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥1:5 and associated 95% CI, directed against to Serogroup B Test Strains at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 6 and month 7 | Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo |
| GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 7 | Antibody response was measured as Geometric Mean Ratio (95% CI), against Serogroup B Test Strains at One Month After the Third Vaccination (month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo |
| Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | From Day 1 to Day 7 after vaccination | Unsolicited AEs were collected with onset from Day 1 through Day 7 After Vaccination. One subject initially randomized to group 3ABCWYqOMV and supposed to receive rMenB+1/4OMV+ACWY as the third vaccination, actually received Tdap as the third vaccination and was included in 2ABCWYqOMV group for the safety analysis. |
| Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 7 | Antibody response was measured as the percentage of subjects with seroresponse Against N meningitidis Serogroups A, C, W and Y, after pre and post vaccination at month 6 and after the third vaccination (month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo. Seroresponse to N meningitidis serogroups A, C, W and Y is defined as: For subjects with a prevaccination hSBA \<1:4, a postvaccination hSBA ≥1:8;For subjects with a prevaccination hSBA ≥1:4, an increase in hSBA titer of at least four times the prevaccination titer. |
| Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 7 | Antibody response was measured as the percentage of subjects with 4-fold Increase in human serum bactericidal assay (hSBA) titers and associated 95% CI, Against Serogroup B Test Strains at One Month After Third Vaccination (month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo |
| GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean hSBA Titers Against N meningitidis Serogroups A, C, W and Y after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo. |
| GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean Ratios (95%CI) Against N meningitidis Serogroups A, C, W and Y after after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 6 and month 7 | Antibody response was measured as Geometric Mean hSBA Titers against N meningitidis Serogroups A, C, W and Y at One of Four MenABCWY Formulations or rMenB at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7) |
| GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean Ratios (95%CI) Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (month 6) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean Ratios (95%CI) Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean Ratios (95%CI) Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| Numbers of Subjects With Other Unsolicited AEs | Day 8 After vaccination Through Study Termination, up to 6 months | Unsolicited AEs were collected from Day 8 After vaccination Through Study Termination. One subject initially randomized to group 3ABCWYqOMV and supposed to receive rMenB+1/4OMV+ACWY as the third vaccination, actually received Tdap as the third vaccination and was included in 2ABCWYqOMV group for the safety analysis. |
| Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | From Day 1 to Day 7 after vaccination | Solicited local and systemic AEs were collected daily for 7 days (day 1 through day 7) after vaccination. One subject initially randomized to group 3ABCWYqOMV and supposed to receive rMenB+1/4OMV+ACWY as the third vaccination, actually received Tdap as the third vaccination and was included in 2ABCWYqOMV group for the safety analysis. |
| GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | At month 1, 3, 6, 7 and 12 | Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, After Third Vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo |
| Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | At month 7 | Antibody response was measured as Geometric Mean Ratio (95% CI), against N meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination (month 7) With One of Four MenABCWY Formulations or rMenB |
Countries
Chile, Colombia, Panama
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 3ABCWY Two doses of MenABCWY vaccine (no outer membrane vesicle {OMV}) in the primary study and one dose of the same vaccine in the current study | 25 |
| 2ABCWY Two doses of MenABCWY vaccine (no OMV) in the primary study and one dose of Tdap in the current study | 49 |
| 3ABx2CWY Two doses of MenABx2CWY vaccine in the primary study and one dose of the same vaccine in the current study | 24 |
| 2ABx2CWY Two doses of MenABx2CWY vaccine in the primary study and one dose of Tdap in the current study | 49 |
| 3ABCWY+OMV Two doses MenABCWY+OMV vaccine in the primary study and one dose of the same vaccine in the current study | 25 |
| 2ABCWY+OMV Two doses MenABCWY+OMV vaccine in the primary study and one dose of Tdap in the current study | 48 |
| 3ABCWYqOMV Two doses of MenABCWY+1/4OMV vaccine in the primary study and one dose of the same vaccine in the current study | 25 |
| 2ABCWYqOMV Two doses of MenABCWY+1/4OMV vaccine in the primary study and one dose of Tdap in the current study | 49 |
| 3 B Two doses of rMenB vaccine in the primary study and one dose of the same vaccine in the current study | 23 |
| 2 B Two doses of rMenB vaccine in the primary study and one dose of Tdap in the current study | 50 |
| 1ACWY One dose of MenACWY vaccine followed by one dose of placebo in the primary study and one dose of Tdap in the current study | 73 |
| Total | 440 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 1 |
| Overall Study | Protocol Violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrew consent | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | 3ABCWY | 2ABCWY | 3ABx2CWY | 2ABx2CWY | 3ABCWY+OMV | 2ABCWY+OMV | 3ABCWYqOMV | 2ABCWYqOMV | 3 B | 2 B | 1ACWY | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 14.3 years STANDARD_DEVIATION 2.2 | 14.2 years STANDARD_DEVIATION 2 | 14.4 years STANDARD_DEVIATION 2.1 | 14.4 years STANDARD_DEVIATION 2.1 | 14.9 years STANDARD_DEVIATION 2.6 | 14.2 years STANDARD_DEVIATION 2.1 | 14.3 years STANDARD_DEVIATION 2 | 14.4 years STANDARD_DEVIATION 2.1 | 14.8 years STANDARD_DEVIATION 2.5 | 15.0 years STANDARD_DEVIATION 2 | 14.8 years STANDARD_DEVIATION 2.1 | 14.5 years STANDARD_DEVIATION 2.1 |
| Sex: Female, Male Female | 16 Participants | 29 Participants | 14 Participants | 27 Participants | 12 Participants | 26 Participants | 14 Participants | 19 Participants | 11 Participants | 25 Participants | 39 Participants | 232 Participants |
| Sex: Female, Male Male | 9 Participants | 20 Participants | 10 Participants | 22 Participants | 13 Participants | 22 Participants | 11 Participants | 30 Participants | 12 Participants | 25 Participants | 34 Participants | 208 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 20 / 24 | 38 / 49 | 20 / 24 | 36 / 49 | 23 / 25 | 37 / 48 | 22 / 24 | 38 / 50 | 19 / 23 | 40 / 50 | 56 / 73 |
| serious Total, serious adverse events | 0 / 24 | 0 / 49 | 1 / 24 | 1 / 49 | 0 / 25 | 0 / 48 | 1 / 24 | 1 / 50 | 0 / 23 | 1 / 50 | 0 / 73 |
Outcome results
Primary
Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥1:5 and associated 95% CI, directed against to Serogroup B Test Strains at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7)
Time frame: At month 6 and month 7
Population: Analysis was done by MITT Month 7 Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 12 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 96 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 80 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=24,23,24,25,23,71) | 96 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 100 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,24,25,22,73) | 92 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 24 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 68 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 20 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,73) | 20 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 40 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=25,21,24,24,21,71) | 16 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,24,25,22,73) | 96 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 35 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 61 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 46 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=24,23,24,25,23,71) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 8 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,73) | 29 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 25 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=25,21,24,24,21,71) | 38 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 79 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 96 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=24,23,24,25,23,71) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 29 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 95 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 39 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,73) | 88 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=25,21,24,24,21,71) | 25 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 87 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 32 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 52 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,24,25,22,73) | 96 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 92 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 52 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 12 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,24,25,22,73) | 92 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=25,21,24,24,21,71) | 33 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 88 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 16 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 29 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,73) | 76 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=24,23,24,25,23,71) | 96 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=24,23,24,25,23,71) | 96 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 35 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,24,25,22,73) | 91 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 100 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 100 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 9 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,73) | 17 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 17 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 64 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 30 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 62 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=25,21,24,24,21,71) | 33 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 29 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 8 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 6 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,73) | 1 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 0 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=24,23,24,25,23,71) | 4 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=25,21,24,24,21,71) | 4 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 16 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 15 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,24,25,22,73) | 4 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 30 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:5 Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 3 Percentages of subjects |
Primary
Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as the percentage of subjects with human serum bactericidal assay (hSBA) titers ≥1:8 and associated 95% CI, directed against to N meningitidis serogroups A, C, W, and Y at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7).
Time frame: At month 6 and month 7
Population: Analysis was done by Modified Intention-To-Treat (MITT) Month 7 Set. MITT is defined as all subjects in the enrolled set who received a study vaccination at Month 6 and provided one evaluable serum sample at Month 7.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 96 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 52 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 100 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 100 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 100 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 100 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 100 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 96 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 96 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 100 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 79 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 96 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 96 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 100 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 75 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 68 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 92 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 100 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 100 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 35 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 91 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 33 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 73 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 55 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 90 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 4 Percentages of subjects |
| 3 B | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 14 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 85 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 85 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 68 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 58 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 55 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 76 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 96 Percentages of subjects |
| 1ACWY | Percentages of Subjects With hSBA ≥1:8 Against Serogroups A, C, W and Y at One Month After the Third Vaccination With Either One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 97 Percentages of subjects |
Secondary
Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as Geometric Mean Ratio (95% CI), against N meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination (month 7) With One of Four MenABCWY Formulations or rMenB
Time frame: At month 7
Population: Analysis was done by MITT Month 7 Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 15 Ratio |
| 3ABCWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 3.43 Ratio |
| 3ABCWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 3.42 Ratio |
| 3ABCWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 3.33 Ratio |
| 3ABx2CWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 3.66 Ratio |
| 3ABx2CWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 4.63 Ratio |
| 3ABx2CWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 7.53 Ratio |
| 3ABx2CWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 2.68 Ratio |
| 3ABCWY+OMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 4.45 Ratio |
| 3ABCWY+OMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 3.98 Ratio |
| 3ABCWY+OMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 3.85 Ratio |
| 3ABCWY+OMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 10 Ratio |
| 3ABCWYqOMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 14 Ratio |
| 3ABCWYqOMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 3.32 Ratio |
| 3ABCWYqOMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 5.01 Ratio |
| 3ABCWYqOMV | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 4.05 Ratio |
| 3 B | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 11 Ratio |
| 3 B | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 1.46 Ratio |
| 3 B | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 8.41 Ratio |
| 3 B | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 34 Ratio |
| 1ACWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 0.75 Ratio |
| 1ACWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 1.01 Ratio |
| 1ACWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 0.81 Ratio |
| 1ACWY | Geometric Mean Ratio (GMR) for (95%CI) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 1.05 Ratio |
Secondary
Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as Geometric Mean hSBA Titers against N meningitidis Serogroups A, C, W and Y at One of Four MenABCWY Formulations or rMenB at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7)
Time frame: At month 6 and month 7
Population: Analysis was done by MITT Month 7 Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 211 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 15 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 247 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 796 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 189 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 710 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 203 Titers |
| 3ABCWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 695 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 716 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 629 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 44 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 233 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 695 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 153 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 322 Titers |
| 3ABx2CWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 184 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 242 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 168 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 670 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 619 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 202 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 929 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 158 Titers |
| 3ABCWY+OMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 31 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 21 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 684 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 164 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 274 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 137 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 634 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 432 Titers |
| 3ABCWYqOMV | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 129 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 2.64 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 11 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 4.52 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 126 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 1.72 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 4.54 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 135 Titers |
| 3 B | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 31 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 19 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 97 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 25 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 128 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 130 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 22 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 85 Titers |
| 1ACWY | Geometric Mean Titers (GMT) for N Meningitidis Serogroups A, C, W and Y at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 21 Titers |
Secondary
GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean Ratios (95%CI) Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=24,23,22,20,23,66) | 1.28 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 83 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,21,21,70) | 3.41 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 12(n=24,22,19,21,23,64) | 1.03 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1.25 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,22,22,72) | 10 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 4.22 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 221 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 48 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,22,23,70) | 226 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,22,23,70) | 1.73 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,23,22,23,71) | 2.33 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 23 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=24,22,20,21,21,66) | 4.55 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=24,23,20,18,22,65) | 1.52 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,22,23,69) | 4.41 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 12(n=23,21,20,22,22,71) | 5.61 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,22,23,71) | 1.46 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 131 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=24,22,21,21,23,65) | 1.22 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 4.47 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 3.79 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 0.81 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,22,23,71) | 1.35 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 31 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 58 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,23,22,23,69) | 31 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 1.33 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 1.67 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.11 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 7.44 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 344 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,23,22,23,71) | 8.23 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 1.86 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1.32 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 95 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 11 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 12(n=23,21,20,22,22,71) | 19 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 12(n=24,22,19,21,23,64) | 1.07 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=24,22,20,21,21,66) | 3.1 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 86 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,22,23,70) | 401 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=24,22,21,21,23,65) | 1.14 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 5.06 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=24,23,20,18,22,65) | 1.82 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=24,23,22,20,23,66) | 1.19 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 113 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,22,23,71) | 1.97 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,22,22,72) | 16 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,21,21,70) | 7.46 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,22,23,70) | 2.02 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,22,23,69) | 11 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 60 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,22,23,71) | 2.18 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 197 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,23,22,23,69) | 190 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.13 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 1.93 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 56 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.1 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=24,23,20,18,22,65) | 4.54 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 17 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 111 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 8.28 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 16 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 14 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 182 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 24 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 325 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 62 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 3.63 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 10 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.93 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 13 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 2.81 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,22,23,71) | 3.46 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,22,23,69) | 17 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,22,23,70) | 3.1 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,22,22,72) | 31 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,22,23,71) | 4.57 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=24,23,22,20,23,66) | 2.5 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 126 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=24,22,21,21,23,65) | 2.14 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=24,22,20,21,21,66) | 12 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 12(n=24,22,19,21,23,64) | 3.56 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,23,22,23,71) | 4.84 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,23,22,23,69) | 105 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,21,21,70) | 5.97 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,22,23,70) | 336 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 12(n=23,21,20,22,22,71) | 14 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,23,22,23,71) | 4.48 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,21,21,70) | 7.56 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,22,22,72) | 13 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 244 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 95 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 5.16 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,22,23,71) | 1.83 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 39 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 8.95 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=24,22,20,21,21,66) | 7.7 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,22,23,71) | 2.12 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,22,23,70) | 236 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=24,23,22,20,23,66) | 2.1 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 90 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 4.31 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=24,22,21,21,23,65) | 1.62 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=24,23,20,18,22,65) | 2.81 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1.71 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 19 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 58 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 182 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,22,23,69) | 8.26 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 6.66 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,22,23,70) | 1.66 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.37 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 6.45 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 12(n=23,21,20,22,22,71) | 16 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.06 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,23,22,23,69) | 177 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 12(n=24,22,19,21,23,64) | 1.73 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 435 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 1.59 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 233 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,23,22,23,69) | 196 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.06 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 79 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,22,23,71) | 1.64 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=24,23,22,20,23,66) | 1.55 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,22,23,69) | 7.4 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 6.97 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,22,23,70) | 1.77 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 79 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,22,22,72) | 8.18 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,21,21,70) | 6.57 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,22,23,71) | 2.16 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 4.7 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=24,23,20,18,22,65) | 2.56 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 53 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 12(n=23,21,20,22,22,71) | 34 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=24,22,21,21,23,65) | 1.42 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=24,22,20,21,21,66) | 4.15 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 3.92 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,22,23,70) | 428 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 12(n=24,22,19,21,23,64) | 2.24 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,23,22,23,71) | 3.12 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 138 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1.06 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 1.64 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 79 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.09 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 0.8 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,22,23,71) | 1.03 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 0.92 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 0.99 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 12(n=24,22,19,21,23,64) | 1.19 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,22,23,70) | 1.07 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,22,23,70) | 0.99 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,22,23,69) | 1.04 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 0.78 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 0.76 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 0.7 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 0.86 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 0.86 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,23,22,23,71) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,22,23,71) | 0.95 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 12(n=23,21,20,22,22,71) | 1.03 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=24,23,20,18,22,65) | 1.13 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 1.05 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,23,22,23,69) | 1.28 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,22,22,72) | 0.97 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=24,22,21,21,23,65) | 1.2 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=24,23,22,20,23,66) | 1.02 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 1.15 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,21,21,70) | 1.05 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 0.89 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 0.77 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=24,22,20,21,21,66) | 1.21 Ratio |
Secondary
GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean Ratios (95%CI) Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (month 6) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 7 (n=47,47,44,45,50,72) | 1.4 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 3 (n=48,46,40,40,49,69) | 57 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=44,43,36,43,50,64) | 1.38 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,48,50,72) | 18 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=43,43,41,40,50,71) | 3.17 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,48,50,73) | 23 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 6 (n=47,46,45,44,50,70) | 1.65 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=48,49,48,47,49,72) | 0.99 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,47,47,47,50,72) | 6.3 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 3 (n=49,48,47,47,50,72) | 1.74 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 3 (n=47,45,33,40,49,65) | 1.62 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,45,50,72) | 13 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=47,45,37,44,50,66) | 1.07 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=46,46,44,44,48,70) | 7.07 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=44,46,44,44,50,70) | 4.46 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 1 (n=48,48,48,48,50,72) | 1.27 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 7(n=46,45,36,43,50,66) | 1.29 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 1 (n=48,47,44,45,50,71) | 1.57 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,47,45,47,50,72) | 61 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 12 (n=45,47,46,45,50,72) | 0.91 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=46,45,37,43,49,65) | 1.39 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 1 (n=48,42,42,44,50,71) | 4.42 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 3 (n=49,47,42,41,50,69) | 4.96 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,46,50,71) | 106 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 12 (n=45,46,42,43,50,71) | 1.35 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,46,44,45,50,71) | 2.58 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,47,46,48,49,73) | 3.73 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,47,47,48,50,73) | 4.42 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=47,48,47,48,50,73) | 0.85 Ratio |
| 3ABCWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,47,48,72) | 28 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,47,45,47,50,72) | 84 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=46,45,37,43,49,65) | 1.13 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 7 (n=47,47,44,45,50,72) | 1.82 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 12 (n=45,46,42,43,50,71) | 1.26 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 3 (n=47,45,33,40,49,65) | 2.1 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=47,45,37,44,50,66) | 1.14 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,48,50,72) | 42 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,47,47,47,50,72) | 5.94 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,47,47,48,50,73) | 7.99 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,46,50,71) | 184 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,47,48,72) | 56 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,47,46,48,49,73) | 4.34 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=43,43,41,40,50,71) | 3.77 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,48,50,73) | 44 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=44,46,44,44,50,70) | 7.43 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,45,50,72) | 21 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 1 (n=48,48,48,48,50,72) | 1.46 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=46,46,44,44,48,70) | 13 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 3 (n=49,48,47,47,50,72) | 2.33 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 3 (n=48,46,40,40,49,69) | 145 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=48,49,48,47,49,72) | 1.14 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=47,48,47,48,50,73) | 1.07 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 1 (n=48,42,42,44,50,71) | 5.08 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 12 (n=45,47,46,45,50,72) | 0.97 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,46,44,45,50,71) | 1.77 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=44,43,36,43,50,64) | 0.94 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 1 (n=48,47,44,45,50,71) | 2.09 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 3 (n=49,47,42,41,50,69) | 10 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 7(n=46,45,36,43,50,66) | 1.05 Ratio |
| 3ABx2CWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 6 (n=47,46,45,44,50,70) | 2.04 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,47,45,47,50,72) | 87 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,47,48,72) | 29 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 1 (n=48,42,42,44,50,71) | 3.77 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=43,43,41,40,50,71) | 4.65 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 3 (n=47,45,33,40,49,65) | 4.46 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=47,48,47,48,50,73) | 1.53 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,46,50,71) | 176 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=46,45,37,43,49,65) | 1.91 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,47,47,48,50,73) | 12 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,48,50,72) | 12 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 3 (n=49,47,42,41,50,69) | 13 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 12 (n=45,47,46,45,50,72) | 1.41 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,47,47,47,50,72) | 7.37 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=44,43,36,43,50,64) | 1.7 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 6 (n=47,46,45,44,50,70) | 2.58 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=47,45,37,44,50,66) | 2.6 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 7 (n=47,47,44,45,50,72) | 2.08 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 1 (n=48,48,48,48,50,72) | 2.91 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=46,46,44,44,48,70) | 9.18 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 1 (n=48,47,44,45,50,71) | 3.61 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,45,50,72) | 15 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=44,46,44,44,50,70) | 6.03 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,46,44,45,50,71) | 3.11 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 3 (n=49,48,47,47,50,72) | 8.25 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,47,46,48,49,73) | 4.75 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 3 (n=48,46,40,40,49,69) | 105 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 12 (n=45,46,42,43,50,71) | 1.86 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,48,50,73) | 23 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 7(n=46,45,36,43,50,66) | 1.81 Ratio |
| 3ABCWY+OMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=48,49,48,47,49,72) | 1.86 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 6 (n=47,46,45,44,50,70) | 2.46 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,47,47,47,50,72) | 11 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,47,46,48,49,73) | 8.48 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,46,44,45,50,71) | 3.41 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,48,50,72) | 16 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,46,50,71) | 174 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,47,48,72) | 35 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,48,50,73) | 29 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 1 (n=48,48,48,48,50,72) | 2.51 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 3 (n=49,48,47,47,50,72) | 7.17 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=48,49,48,47,49,72) | 1.79 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=47,48,47,48,50,73) | 1.45 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 12 (n=45,47,46,45,50,72) | 1.25 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 1 (n=48,47,44,45,50,71) | 2.73 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 3 (n=49,47,42,41,50,69) | 15 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,45,50,72) | 18 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 7 (n=47,47,44,45,50,72) | 2.75 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 12 (n=45,46,42,43,50,71) | 1.96 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=47,45,37,44,50,66) | 2.03 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 3 (n=47,45,33,40,49,65) | 4.94 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=46,45,37,43,49,65) | 2.53 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 7(n=46,45,36,43,50,66) | 2.41 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=44,43,36,43,50,64) | 2.24 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 1 (n=48,42,42,44,50,71) | 3.35 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 3 (n=48,46,40,40,49,69) | 89 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=46,46,44,44,48,70) | 4.78 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=44,46,44,44,50,70) | 3.11 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=43,43,41,40,50,71) | 2.52 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,47,47,48,50,73) | 8.82 Ratio |
| 3ABCWYqOMV | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,47,45,47,50,72) | 103 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 6 (n=47,46,45,44,50,70) | 1.53 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=46,45,37,43,49,65) | 1.07 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 3 (n=49,47,42,41,50,69) | 3.54 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 7(n=46,45,36,43,50,66) | 1.12 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 1 (n=48,47,44,45,50,71) | 1.57 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 12 (n=45,47,46,45,50,72) | 0.6 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,46,44,45,50,71) | 1.85 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=44,43,36,43,50,64) | 0.94 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=47,48,47,48,50,73) | 0.73 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 1 (n=48,42,42,44,50,71) | 3.35 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=48,49,48,47,49,72) | 0.75 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 3 (n=49,48,47,47,50,72) | 1.46 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,47,47,47,50,72) | 3.31 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 3 (n=48,46,40,40,49,69) | 64 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 1 (n=48,48,48,48,50,72) | 1.08 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,47,45,47,50,72) | 32 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=46,46,44,44,48,70) | 5.32 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,45,50,72) | 11 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,48,50,73) | 23 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=44,46,44,44,50,70) | 4.29 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,47,48,72) | 25 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,47,46,48,49,73) | 2.66 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=43,43,41,40,50,71) | 2.17 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,46,50,71) | 107 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,48,50,72) | 21 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=47,45,37,44,50,66) | 1.31 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 12 (n=45,46,42,43,50,71) | 1.05 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,47,47,48,50,73) | 3.53 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 3 (n=47,45,33,40,49,65) | 1.91 Ratio |
| 3 B | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 7 (n=47,47,44,45,50,72) | 1.3 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 7 (n=47,47,44,45,50,72) | 0.97 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,48,50,72) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=46,45,37,43,49,65) | 1.2 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 3 (n=49,47,42,41,50,69) | 1.04 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 6 (n=46,46,44,44,48,70) | 1.05 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 1 (n=48,47,44,45,50,71) | 0.95 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,46,44,45,50,71) | 0.86 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,47,47,48,50,73) | 1.15 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 7(n=46,45,36,43,50,66) | 1.21 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,48,50,73) | 0.86 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 12 (n=45,47,46,45,50,72) | 0.77 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,47,47,47,50,72) | 0.89 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,47,45,47,50,72) | 1.05 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 6 (n=47,46,45,44,50,70) | 0.99 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=44,43,36,43,50,64) | 1.19 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=47,48,47,48,50,73) | 0.8 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 7 (n=44,46,44,44,50,70) | 1.07 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=48,49,48,47,49,72) | 0.76 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,47,46,48,49,73) | 0.92 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,47,48,72) | 0.78 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 1 (n=48,42,42,44,50,71) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=47,45,37,44,50,66) | 1.02 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 3 (n=49,48,47,47,50,72) | 0.99 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,46,50,71) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459(fHBP) - month 12 (n=45,46,42,43,50,71) | 1.03 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 3 (n=47,45,33,40,49,65) | 1.13 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 3 (n=48,46,40,40,49,69) | 1.28 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254(PorA) - month 1 (n=48,48,48,48,50,72) | 1 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=43,43,41,40,50,71) | 1.03 Ratio |
| 1ACWY | GMR Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,45,50,72) | 0.7 Ratio |
Secondary
GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean Ratios (95%CI) Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 15 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 32 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 36 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 123 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,70) | 23 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 25 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 6.44 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 15 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=24,22,19,24,23,69) | 11 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 11 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 43 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 24 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 6.45 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,71) | 37 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,71) | 115 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 99 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 56 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,69) | 33 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,70) | 80 Ratio |
| 3ABCWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 190 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 24 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 9.65 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 67 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 35 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 9.27 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 71 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 214 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 42 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 35 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 9.78 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,70) | 19 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 29 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,70) | 81 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 115 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,69) | 31 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=24,22,19,24,23,69) | 15 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,71) | 146 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 43 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 176 Ratio |
| 3ABx2CWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,71) | 41 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 13 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=24,22,19,24,23,69) | 15 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 30 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 41 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,69) | 33 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 129 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 150 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 43 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 9.6 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,71) | 33 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 36 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 43 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,71) | 139 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,70) | 26 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 13 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 35 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 201 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 25 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 24 Ratio |
| 3ABCWY+OMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,70) | 75 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 34 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 14 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 25 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 81 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 41 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 187 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 33 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 28 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,70) | 14 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,70) | 63 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,69) | 22 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,71) | 100 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,71) | 30 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 6.3 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 109 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 14 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 6.36 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 26 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=24,22,19,24,23,69) | 9.44 Ratio |
| 3ABCWYqOMV | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 15 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 0.81 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 3.69 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 4.78 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,71) | 2.01 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,71) | 9.09 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,69) | 1.16 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,70) | 5.17 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 0.39 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=24,22,19,24,23,69) | 0.75 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,70) | 1.51 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 3.45 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 8.75 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 110 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 1.13 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 1.02 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 0.33 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 0.55 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 0.45 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 79 Ratio |
| 3 B | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 5.42 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 7.27 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 78 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 26 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 15 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 15 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 11 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,70) | 16 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,69) | 5.14 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,71) | 3.9 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,71) | 3.06 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 10 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 7.32 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 5.17 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 5.47 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=24,22,19,24,23,69) | 3.62 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 16 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 12 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 14 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 12 Ratio |
| 1ACWY | GMR Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,70) | 9.54 Ratio |
Secondary
GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as Geometric Mean Ratio (95% CI), against Serogroup B Test Strains at One Month After the Third Vaccination (month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Time frame: At month 7
Population: Analysis was done by MITT Month 7 Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 18 Ratio |
| 3ABCWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 6.96 Ratio |
| 3ABCWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 1.21 Ratio |
| 3ABCWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 5.99 Ratio |
| 3ABCWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 3.61 Ratio |
| 3ABCWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 65 Ratio |
| 3ABx2CWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 6.04 Ratio |
| 3ABx2CWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 8.1 Ratio |
| 3ABx2CWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 50 Ratio |
| 3ABx2CWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 22 Ratio |
| 3ABx2CWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 1.76 Ratio |
| 3ABx2CWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 2.46 Ratio |
| 3ABCWY+OMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 65 Ratio |
| 3ABCWY+OMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 5.18 Ratio |
| 3ABCWY+OMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 9.08 Ratio |
| 3ABCWY+OMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 6.56 Ratio |
| 3ABCWY+OMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 14 Ratio |
| 3ABCWY+OMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 14 Ratio |
| 3ABCWYqOMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 8.58 Ratio |
| 3ABCWYqOMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 6.25 Ratio |
| 3ABCWYqOMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 6.29 Ratio |
| 3ABCWYqOMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 40 Ratio |
| 3ABCWYqOMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 3.92 Ratio |
| 3ABCWYqOMV | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 22 Ratio |
| 3 B | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 16 Ratio |
| 3 B | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 2.75 Ratio |
| 3 B | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 5.47 Ratio |
| 3 B | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 1.45 Ratio |
| 3 B | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 4.37 Ratio |
| 3 B | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 66 Ratio |
| 1ACWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 1.01 Ratio |
| 1ACWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 1.05 Ratio |
| 1ACWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 1.01 Ratio |
| 1ACWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 1 Ratio |
| 1ACWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 1.12 Ratio |
| 1ACWY | GMR for (95%CI) for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 1.03 Ratio |
Secondary
GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean Ratios (95%CI) Against N meningitidis Serogroups A, C, W and Y after after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by Per MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,45,47,46,50,72) | 20 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,45,50,71) | 6.97 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,47,48,49,49,73) | 21 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,46,50,70) | 72 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,46,45,45,45,72) | 9.21 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,47,47,46,49,72) | 9.2 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,48,50,71) | 16 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,47,47,49,50,73) | 44 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,46,45,46,50,70) | 18 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,46,45,43,43,69) | 11 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,44,50,71) | 12 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 19 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,44,45,42,46,69) | 7.33 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,47,48,48,49,72) | 44 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,46,49,69) | 29 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,47,50,71) | 24 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,47,50,72) | 107 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,47,50,70) | 11 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,48,50,70) | 41 Ratio |
| 3ABCWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,47,46,49,50,72) | 37 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,45,50,71) | 7.18 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,45,47,46,50,72) | 27 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,47,47,46,49,72) | 13 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,46,45,46,50,70) | 25 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,44,50,71) | 16 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,46,50,70) | 114 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,46,45,45,45,72) | 8.17 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,47,50,71) | 33 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,47,50,70) | 26 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,44,45,42,46,69) | 6.54 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,47,46,49,50,72) | 45 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,47,48,49,49,73) | 26 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,46,49,69) | 41 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,48,50,71) | 21 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,47,47,49,50,73) | 59 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 32 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,47,50,72) | 150 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,47,48,48,49,72) | 56 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,46,45,43,43,69) | 9.75 Ratio |
| 3ABx2CWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,48,50,70) | 45 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,46,45,46,50,70) | 10 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,45,47,46,50,72) | 12 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,46,45,43,43,69) | 5.44 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,46,45,45,45,72) | 4.84 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,44,45,42,46,69) | 3.52 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,47,48,49,49,73) | 15 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,47,47,49,50,73) | 37 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,47,48,48,49,72) | 27 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,47,46,49,50,72) | 19 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,47,50,71) | 16 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,44,50,71) | 8.88 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,47,47,46,49,72) | 7.41 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,48,50,70) | 36 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,47,50,72) | 135 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 15 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,48,50,71) | 12 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,45,50,71) | 6.61 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,47,50,70) | 19 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,46,50,70) | 60 Ratio |
| 3ABCWY+OMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,46,49,69) | 22 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,44,45,42,46,69) | 4.83 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,46,45,45,45,72) | 7.94 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,47,50,70) | 20 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,47,48,49,49,73) | 20 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,47,48,48,49,72) | 33 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,46,50,70) | 71 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,47,50,71) | 25 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,44,50,71) | 15 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,47,50,72) | 137 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,46,45,46,50,70) | 16 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,47,46,49,50,72) | 26 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,47,47,49,50,73) | 47 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,45,47,46,50,72) | 19 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 20 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,47,47,46,49,72) | 10 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,46,49,69) | 31 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,48,50,71) | 14 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,46,45,43,43,69) | 9.75 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,45,50,71) | 6.42 Ratio |
| 3ABCWYqOMV | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,48,50,70) | 30 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,47,50,72) | 34 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,44,45,42,46,69) | 0.49 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,48,50,70) | 2.25 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,47,47,49,50,73) | 0.8 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,47,50,70) | 1.42 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,46,49,69) | 1.07 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,48,50,71) | 2.41 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,46,45,43,43,69) | 0.58 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,45,47,46,50,72) | 4.83 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,47,48,48,49,72) | 0.35 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 3.19 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,47,50,71) | 0.85 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,46,45,45,45,72) | 0.55 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,47,47,46,49,72) | 1.15 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,46,45,46,50,70) | 0.27 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,46,50,70) | 2.36 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,47,46,49,50,72) | 0.35 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,44,50,71) | 0.99 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,45,50,71) | 1.68 Ratio |
| 3 B | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,47,48,49,49,73) | 1.02 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,47,50,71) | 3.9 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,46,50,70) | 9.54 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,47,47,46,49,72) | 10 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,46,45,45,45,72) | 5.47 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,47,48,48,49,72) | 14 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,48,50,70) | 78 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,47,47,49,50,73) | 12 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,45,47,46,50,72) | 7.32 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,47,50,72) | 26 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 15 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,47,48,49,49,73) | 16 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,48,50,71) | 15 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,44,45,42,46,69) | 3.62 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,45,50,71) | 11 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,46,49,69) | 5.14 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,47,50,70) | 16 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,46,45,43,43,69) | 5.17 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,47,46,49,50,72) | 12 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,46,45,46,50,70) | 7.27 Ratio |
| 1ACWY | GMR for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,44,50,71) | 3.06 Ratio |
Secondary
GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 140 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 5.42 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,24,25,23,72) | 2.94 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 530 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 75 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 328 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 54 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=25,23,21,25,23,70) | 2.77 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,24,25,23,71) | 294 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,24,21,71) | 4.39 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=25,23,22,25,21,72) | 12 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=25,23,23,25,23,70) | 3.27 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=25,24,23,23,23,72) | 3.42 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,25,23,72) | 1.79 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 62 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,24,24,23,70) | 41 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,25,22,73) | 14 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,25,23,71) | 2.25 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,24,23,70) | 5.94 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 5.75 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=23,21,20,25,22,72) | 7.32 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,25,23,72) | 1.87 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 4.84 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.41 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 2.3 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 108 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=25,24,22,21,22,68) | 4.04 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.9 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 2.87 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 2.13 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.94 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,25,23,72) | 2.78 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 14 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 115 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 6.56 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 149 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 9.63 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 128 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 426 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 122 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 741 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 202 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 2.22 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 3.14 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.85 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 3.24 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,24,23,70) | 15 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,25,23,71) | 2.64 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,25,22,73) | 23 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,25,23,72) | 2.63 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=25,24,23,23,23,72) | 3.23 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=25,24,22,21,22,68) | 5.1 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=25,23,23,25,23,70) | 3.21 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=25,23,22,25,21,72) | 8.91 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=25,23,21,25,23,70) | 3.05 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,24,25,23,72) | 10 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,24,24,23,70) | 245 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,24,21,71) | 9.54 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,24,25,23,71) | 513 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=23,21,20,25,22,72) | 24 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 6.22 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 5.01 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 126 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,25,23,72) | 5.99 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,25,22,73) | 41 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 11 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,25,23,72) | 4.4 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=23,21,20,25,22,72) | 17 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 153 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,25,23,71) | 4 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,24,23,70) | 22 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 29 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 674 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,24,25,23,72) | 6 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 18 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 22 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=25,23,21,25,23,70) | 9.99 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=25,23,22,25,21,72) | 33 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 169 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 48 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 3.33 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,24,24,23,70) | 126 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 22 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=25,23,23,25,23,70) | 5.91 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=25,24,22,21,22,68) | 12 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,24,21,71) | 7.3 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 23 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 367 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=25,24,23,23,23,72) | 6.8 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,24,25,23,71) | 409 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=25,23,21,25,23,70) | 4.92 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 127 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 2.92 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 118 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 8.95 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=23,21,20,25,22,72) | 19 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.83 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 12 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 5.41 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 2.39 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,25,23,72) | 2.69 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,24,21,71) | 9.08 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,24,23,70) | 11 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 110 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,25,23,71) | 2.11 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,25,22,73) | 17 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,25,23,72) | 2.35 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=25,24,23,23,23,72) | 5.73 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,24,25,23,71) | 280 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=25,24,22,21,22,68) | 8.09 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 11 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=25,23,23,25,23,70) | 4.57 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,24,25,23,72) | 5.52 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=25,23,22,25,21,72) | 22 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 42 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 382 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 8.09 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 84 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,24,24,23,70) | 205 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 527 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.79 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 856 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,25,23,72) | 2.8 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 5.03 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 6.1 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 454 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=25,24,23,23,23,72) | 4.07 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,24,24,23,70) | 226 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 104 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=25,24,22,21,22,68) | 6.48 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,24,25,23,71) | 507 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=25,23,23,25,23,70) | 3.67 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.83 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=25,23,22,25,21,72) | 11 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 156 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 2.75 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=25,23,21,25,23,70) | 5.74 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,24,25,23,72) | 3.84 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 2.65 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 274 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 157 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 71 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,24,23,70) | 9.66 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 9.02 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,24,21,71) | 7.87 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1.76 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,25,23,71) | 2.27 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,25,23,72) | 2.08 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,25,22,73) | 11 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=23,21,20,25,22,72) | 41 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,24,24,21,71) | 1.18 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=25,23,21,25,23,70) | 2.91 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 1.74 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 (n=25,23,21,25,23,72) | 1.37 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364(NadA) - month 12 (n=23,21,20,25,22,72) | 1.15 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=24,24,25,24,23,71) | 2.11 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=25,24,24,25,23,73) | 1.2 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=25,23,21,25,23,72) | 1.15 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=23,24,24,25,23,72) | 1.12 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 1 (n=25,24,23,23,23,72) | 2.68 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=25,23,21,25,23,71) | 1.13 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 1.18 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=25,24,24,25,23,72) | 1.26 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=25,24,24,25,23,72) | 1.51 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=25,24,22,21,22,68) | 2.85 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=25,23,21,25,23,72) | 1.53 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=25,24,24,24,23,70) | 1.41 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=25,24,24,25,23,72) | 1.15 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 1.93 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=25,24,24,24,23,73) | 1.51 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=25,23,23,25,23,70) | 2.99 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=25,24,25,25,23,71) | 1.28 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,24,25,23,71) | 1.18 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=25,24,25,24,23,72) | 1.49 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=25,24,24,25,23,72) | 2.27 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=25,23,22,25,21,72) | 3.03 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=25,24,23,25,22,73) | 1.28 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=25,24,24,25,23,72) | 1.27 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=25,24,25,24,23,70) | 1.29 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0, 2 and 6 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=25,24,24,25,22,73) | 1.21 Titers |
Secondary
GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, After Third Vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 ( n=45,47,45,47,50,72) | 1.73 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=48,48,48,49,50,72) | 2.14 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=47,47,48,48,50,71) | 2.1 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=45,47,46,46,50,72) | 1.57 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=48,48,44,42,49,70) | 67 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,47,50,71) | 257 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=47,48,47,49,50,73) | 1.45 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month12 (n=43,45,44,44,50,72) | 3.85 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,46,50,72) | 31 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=48,44,46,48,50,72) | 5.46 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,48,47,49,49,73) | 4.62 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,48,48,72) | 69 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=48,49,48,48,49,72) | 1.7 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,49,50,73) | 55 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,48,48,49,50,73) | 5.56 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=47,48,47,48,50,72) | 3.51 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=47,48,47,49,50,73) | 1.79 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=49,48,45,43,50,70) | 6.31 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=48,48,47,49,50,72) | 1.99 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=47,48,48,48,49,70) | 3.78 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=48,48,42,45,49,68) | 4.34 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,48,48,48,50,72) | 7.87 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=44,48,48,48,50,71) | 5.38 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,47,45,46,50,71) | 3.24 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=48,48,48,48,50,72) | 2.88 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=49,48,47,48,50,72) | 2.98 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,48,46,48,50,72) | 74 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=46,48,48,48,48,71) | 8.59 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=45,46,45,47,50,70) | 3.71 Titers |
| 3ABCWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,49,50,72) | 44 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=47,48,47,49,50,73) | 1.76 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=44,48,48,48,50,71) | 9.65 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=49,48,45,43,50,70) | 13 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 ( n=45,47,45,47,50,72) | 1.64 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=47,47,48,48,50,71) | 2.63 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=47,48,47,49,50,73) | 2.4 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,48,47,49,49,73) | 5.75 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month12 (n=43,45,44,44,50,72) | 4.79 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=46,48,48,48,48,71) | 17 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,47,45,46,50,71) | 2.31 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,49,50,72) | 91 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,48,46,48,50,72) | 114 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=48,48,44,42,49,70) | 192 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,47,50,71) | 401 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=48,44,46,48,50,72) | 6.42 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,48,48,72) | 122 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,49,50,73) | 96 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=47,48,48,48,49,70) | 3.3 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,46,50,72) | 46 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=45,46,45,47,50,70) | 2.82 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=48,48,48,49,50,72) | 2.42 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=49,48,47,48,50,72) | 3.86 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=47,48,47,48,50,72) | 3.19 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=48,49,48,48,49,72) | 1.88 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,48,48,48,50,72) | 7.76 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,48,48,49,50,73) | 10 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=48,48,47,49,50,72) | 2.66 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=48,48,42,45,49,68) | 6.27 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=45,47,46,46,50,72) | 1.6 Titers |
| 3ABx2CWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=48,48,48,48,50,72) | 3.17 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,48,48,48,50,72) | 9.44 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=48,48,48,49,50,72) | 4.95 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=44,48,48,48,50,71) | 7.51 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=48,48,44,42,49,70) | 133 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=47,48,47,48,50,72) | 5.18 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,47,45,46,50,71) | 4 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=48,48,48,48,50,72) | 7.11 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=49,48,47,48,50,72) | 14 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=46,48,48,48,48,71) | 11 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=49,48,45,43,50,70) | 17 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,48,47,49,49,73) | 6.12 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=47,48,47,49,50,73) | 2.75 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 ( n=45,47,45,47,50,72) | 2.43 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=48,49,48,48,49,72) | 3.19 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=48,48,47,49,50,72) | 4.59 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=45,47,46,46,50,72) | 2.47 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=47,48,48,48,49,70) | 5.43 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,48,48,72) | 55 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=48,48,42,45,49,68) | 12 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,49,50,73) | 44 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,48,48,49,50,73) | 15 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=47,47,48,48,50,71) | 3.33 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=48,44,46,48,50,72) | 4.7 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,48,46,48,50,72) | 114 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month12 (n=43,45,44,44,50,72) | 5.76 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,46,50,72) | 30 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,47,50,71) | 337 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=45,46,45,47,50,70) | 4.92 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=47,48,47,49,50,73) | 2.62 Titers |
| 3ABCWY+OMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,49,50,72) | 23 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,48,48,72) | 72 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,48,48,49,50,73) | 11 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,48,46,48,50,72) | 133 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,48,48,48,50,72) | 14 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,48,47,49,49,73) | 11 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,47,45,46,50,71) | 4.31 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,49,50,72) | 34 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,47,50,71) | 363 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,49,50,73) | 59 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,46,50,72) | 35 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=48,48,48,49,50,72) | 4.26 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=49,48,47,48,50,72) | 12 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=48,49,48,48,49,72) | 3.09 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=47,48,47,49,50,73) | 2.49 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=45,47,46,46,50,72) | 2.18 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=48,48,47,49,50,72) | 3.47 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=49,48,45,43,50,70) | 20 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=47,47,48,48,50,71) | 3.15 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=47,48,47,49,50,73) | 3.59 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 ( n=45,47,45,47,50,72) | 2.53 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=48,48,48,48,50,72) | 5.51 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=47,48,47,48,50,72) | 6.58 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=48,48,42,45,49,68) | 14 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=45,46,45,47,50,70) | 6.16 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=47,48,48,48,49,70) | 6.93 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=48,44,46,48,50,72) | 4.24 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=48,48,44,42,49,70) | 125 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=46,48,48,48,48,71) | 6.27 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=44,48,48,48,50,71) | 4.13 Titers |
| 3ABCWYqOMV | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month12 (n=43,45,44,44,50,72) | 3.23 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=45,47,46,46,50,72) | 1.21 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,48,48,48,50,72) | 4.34 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=48,48,48,48,50,72) | 3.76 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=47,48,47,49,50,73) | 1.45 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=48,48,44,42,49,70) | 88 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=44,48,48,48,50,71) | 5.72 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=48,49,48,48,49,72) | 1.47 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month12 (n=43,45,44,44,50,72) | 2.88 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=48,48,42,45,49,68) | 6.25 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=49,48,47,48,50,72) | 2.81 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=47,48,47,48,50,72) | 3.78 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=48,48,48,49,50,72) | 2.01 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,46,50,72) | 32 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=45,46,45,47,50,70) | 3.09 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,49,50,73) | 68 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,48,46,48,50,72) | 44 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=47,48,48,48,49,70) | 3.36 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,48,48,72) | 73 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,47,50,71) | 322 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=48,44,46,48,50,72) | 4.25 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,49,50,72) | 58 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,48,48,49,50,73) | 4.56 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,47,45,46,50,71) | 2.42 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,48,47,49,49,73) | 3.55 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=47,47,48,48,50,71) | 2.05 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=46,48,48,48,48,71) | 7.02 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=47,48,47,49,50,73) | 1.87 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=49,48,45,43,50,70) | 5.04 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 ( n=45,47,45,47,50,72) | 1.44 Titers |
| 3 B | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=48,48,47,49,50,72) | 2.02 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n=48,48,47,49,49,73) | 1.21 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 12 ( n=45,47,45,47,50,72) | 1.37 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 6 (n=47,48,48,48,49,70) | 2.99 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 1 (n=48,48,48,48,50,72) | 2.68 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 7 (n=47,48,47,49,50,73) | 1.2 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month12 (n=43,45,44,44,50,72) | 1.15 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 3 (n=49,48,46,48,50,72) | 1.27 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084(NHBA) - month 12 (n=45,46,45,47,50,70) | 2.91 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 3 (n=49,48,47,47,50,71) | 2.11 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=46,48,48,48,48,71) | 1.18 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 1 (n=48,48,47,49,50,72) | 1.26 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 6 (n=48,49,48,48,49,72) | 1.15 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 1 (n=48,48,48,49,50,73) | 1.51 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 6 (n=47,47,48,48,50,71) | 1.28 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=47,48,48,48,50,72) | 1.18 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 1 (n=48,44,46,48,50,72) | 1.12 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 3 (n=48,48,42,45,49,68) | 2.85 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 3 (n=49,48,47,48,50,72) | 1.49 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 1 (n=48,48,47,49,50,72) | 2.27 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 1 (n=48,48,48,49,50,72) | 1.51 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | NZ98/254 (PorA) - month 12 (n=45,47,46,46,50,72) | 1.15 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M07-0241084 (NHBA) - month 7 (n=47,48,47,48,50,72) | 3.03 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | H44/76 (fHbp) - month 12 (n=45,47,45,46,50,71) | 1.13 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 12 (n=45,47,46,46,50,72) | 1.53 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 7 (n=47,48,47,49,50,73) | 1.28 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=44,48,48,48,50,71) | 1.18 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M01-0240364 (NadA) - month 3 (n=48,48,44,42,49,70) | 1.41 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=47,48,47,49,50,73) | 1.93 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | M14459 (fHBP) - month 3 (n=49,48,45,43,50,70) | 1.29 Titers |
| 1ACWY | GMT Against Serogroup B Test Strains at Month 0 Through Month 12 Following Vaccination at Month 0 and Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=47,49,48,48,48,72) | 1.74 Titers |
Secondary
GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 152 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 648 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 75 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 132 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12(n=24,22,19,24,23,69) | 264 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 33 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 185 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 14 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,72) | 202 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 640 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 42 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,71) | 125 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 676 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 295 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 166 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 225 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 398 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,71) | 482 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 182 Titers |
| 3ABCWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 247 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 590 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 143 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 676 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 252 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,72) | 185 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 216 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 40 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 179 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 48 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 296 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 98 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12(n=24,22,19,24,23,69) | 258 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 58 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 351 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 670 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 176 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,71) | 87 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 455 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,71) | 384 Titers |
| 3ABx2CWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 180 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 44 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 185 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 32 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 253 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 47 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,71) | 112 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,71) | 346 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 157 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 636 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,72) | 153 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 237 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 499 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 191 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 876 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12(n=24,22,19,24,23,69) | 257 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 62 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 214 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 147 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 599 Titers |
| 3ABCWY+OMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 210 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 121 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,71) | 381 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 144 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 408 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 406 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,71) | 74 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 148 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 38 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 627 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12(n=24,22,19,24,23,69) | 212 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 256 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 46 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 71 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 19 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 170 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 205 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 118 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 153 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 553 Titers |
| 3ABCWYqOMV | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,72) | 157 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 4.91 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 4.35 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 1.46 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 4.58 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 19 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,72) | 7.8 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 4.38 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,71) | 5.93 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 98 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12(n=24,22,19,24,23,69) | 17 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 139 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 4.65 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,71) | 20 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 33 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 2.56 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 1.69 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 10 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 116 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 11 Titers |
| 3 B | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 140 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=24,24,24,25,23,72) | 84 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=22,24,24,24,21,70) | 23 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=23,24,21,25,21,72) | 121 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=24,24,21,25,22,71) | 21 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12(n=24,22,19,24,23,69) | 75 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=24,24,24,25,23,70) | 107 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=23,24,24,25,23,69) | 20 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=25,23,21,25,23,72) | 14 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=25,24,23,25,23,73) | 92 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=25,23,21,25,23,70) | 47 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=23,24,23,25,22,72) | 18 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=25,24,25,25,23,73) | 72 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=25,24,25,25,23,72) | 36 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=25,24,24,25,23,72) | 210 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=25,24,24,25,23,71) | 75 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=25,24,25,24,23,71) | 45 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=25,24,25,24,23,72) | 166 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=25,23,21,25,22,71) | 14 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=24,24,25,24,22,69) | 117 Titers |
| 1ACWY | GMT Against Serogroups A, C, W, and Y at Month 0 Through Month 12 Following Vaccination at 0, 2 and 6 Months With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=25,24,24,25,22,72) | 75 Titers |
Secondary
GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as Geometric Mean hSBA Titers Against Serogroup B Test Strains at 6 months following first vaccine during the parent study NCT01210885 and one month after third vaccination (Month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Time frame: At month 6 and month 7
Population: Analysis was done by MITT Month 7 Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,72) | 2.37 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 546 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 3.37 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 1.96 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,23,24,21,71) | 4.62 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 12 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,25,23,71) | 311 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 16 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 5.9 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 2.71 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n= 25,24,24,25,22,73) | 109 Titers |
| 3ABCWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 78 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 3.29 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,72) | 3.26 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 122 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 740 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,25,23,71) | 533 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 3.66 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 1.85 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n= 25,24,24,25,22,73) | 154 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 6.88 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,23,24,21,71) | 9.98 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 27 Titers |
| 3ABx2CWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 9.48 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 6.92 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,72) | 24 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,25,23,71) | 385 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 4.49 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 12 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 38 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 3.47 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 665 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 46 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n= 25,24,24,25,22,73) | 181 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,23,24,21,71) | 6.95 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 45 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 6.45 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 25 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,23,24,21,71) | 7.44 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,25,23,71) | 286 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 5.25 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n= 25,24,24,25,22,73) | 114 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 84 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 527 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 1.89 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,72) | 12 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 2.34 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 20 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 1.81 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 152 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n= 25,24,24,25,22,73) | 109 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 9.73 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,72) | 2.64 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 6.42 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 2.48 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,25,23,71) | 474 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,23,24,21,71) | 7.21 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 3.32 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 12 Titers |
| 3 B | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 832 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 6 (n=25,24,24,25,23,72) | 1.74 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 6 (n=25,24,24,25,23,72) | 1.15 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 6 (n=25,24,25,25,23,71) | 1.28 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 7 (n= 25,24,24,25,22,73) | 1.21 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459(fHBP) - month 7 (n=25,24,23,25,22,73) | 1.28 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 6 (n=25,21,23,24,21,71) | 1.18 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) - month 7 (n=25,24,24,25,23,73) | 1.93 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254(PorA) - month 7 (n=25,24,24,25,23,72) | 1.2 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) - month 6 (n=25,24,25,24,23,72) | 1.18 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 7 (n=25,23,22,25,21,72) | 3.03 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) - month 7 (n=24,23,23,25,23,71) | 1.18 Titers |
| 1ACWY | GMT for N Meningitidis Against Serogroup B Test Strains at One Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084(NHBA) - month 6 (n=25,23,23,25,23,70) | 2.99 Titers |
Secondary
GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo
Antibody response was measured as Geometric Mean hSBA Titers Against N meningitidis Serogroups A, C, W and Y after first (month 1) and second (month 3) vaccination during the parent study NCT01210885, after 6 month of the first vaccination (6 month) in the parent study and after the third vaccination (month 7) and 6 month after the third vaccination (month 12) with One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo.
Time frame: At month 1, 3, 6, 7 and 12
Population: Analysis was done by MITT Set.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,48,48,49,49,73) | 98 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,48,49,70) | 133 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,48,50,71) | 340 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,46,50,72) | 55 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,46,50,71) | 10 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 28 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,48,47,49,50,73) | 214 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,45,45,43,46,69) | 119 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,48,48,48,49,72) | 206 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,48,50,72) | 162 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,48,50,71) | 51 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,47,45,46,50,70) | 88 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,47,45,45,43,69) | 202 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,47,45,47,45,72) | 173 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,49,50,72) | 110 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,49,50,70) | 61 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,46,47,48,50,72) | 370 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,48,46,49,50,72) | 180 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,49,50,71) | 24 Titers |
| 3ABCWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,48,47,48,49,72) | 163 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,47,45,47,45,72) | 167 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,48,47,48,49,72) | 243 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,46,47,48,50,72) | 514 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,47,45,45,43,69) | 196 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 44 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,49,50,70) | 61 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,48,46,49,50,72) | 213 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,49,50,71) | 28 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,48,48,48,49,72) | 249 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,46,50,71) | 9.73 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,47,45,46,50,70) | 112 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,48,50,71) | 116 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,48,47,49,50,73) | 283 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,48,50,71) | 501 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,48,50,72) | 206 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,48,48,49,49,73) | 119 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,48,49,70) | 186 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,49,50,72) | 153 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,45,45,43,46,69) | 113 Titers |
| 3ABx2CWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,46,50,72) | 66 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,48,48,49,49,73) | 76 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,48,47,48,49,72) | 173 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,47,45,46,50,70) | 55 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,46,50,72) | 45 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,48,49,70) | 117 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,48,50,72) | 183 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,49,50,71) | 17 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,45,45,43,46,69) | 83 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 21 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,48,46,49,50,72) | 100 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,49,50,72) | 88 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,49,50,70) | 49 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,48,50,71) | 99 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,48,47,49,50,73) | 195 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,47,45,47,45,72) | 118 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,46,50,71) | 8.88 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,48,48,48,49,72) | 138 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,47,45,45,43,69) | 143 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,48,50,71) | 338 Titers |
| 3ABCWY+OMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,46,47,48,50,72) | 349 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,47,45,45,43,69) | 194 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,49,50,70) | 37 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,48,50,72) | 169 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 24 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,49,50,71) | 17 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,46,50,71) | 8.08 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,48,50,71) | 101 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,48,50,71) | 380 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,48,49,70) | 157 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,49,50,72) | 128 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,46,50,72) | 72 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,48,47,48,49,72) | 233 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,46,47,48,50,72) | 435 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,47,45,47,45,72) | 168 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,45,45,43,46,69) | 109 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,48,48,49,49,73) | 92 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,48,47,49,50,73) | 226 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,48,48,48,49,72) | 154 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,48,46,49,50,72) | 127 Titers |
| 3ABCWYqOMV | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,47,45,46,50,70) | 75 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,46,50,72) | 6.03 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,47,45,47,45,72) | 13 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,49,50,72) | 5.53 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,48,50,72) | 44 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,45,45,43,46,69) | 11 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,48,49,70) | 6.77 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,48,50,71) | 17 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,48,48,49,49,73) | 5.6 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,48,50,71) | 8.76 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,49,50,70) | 2.96 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,48,47,49,50,73) | 4.7 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,46,50,71) | 2.21 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,49,50,71) | 3.18 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,48,48,48,49,72) | 1.93 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 4.22 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,47,45,46,50,70) | 1.59 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,48,46,49,50,72) | 2.05 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,46,47,48,50,72) | 140 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,47,45,45,43,69) | 15 Titers |
| 3 B | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,48,47,48,49,72) | 29 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 3 (n=49,48,47,48,50,72) | 36 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 7 (n=46,48,46,49,50,72) | 75 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 3 (n=49,48,47,49,50,73) | 72 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 7 (n=46,47,45,47,45,72) | 121 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 7 (n=48,47,46,49,50,72) | 18 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 1 (n=48,48,47,48,49,72) | 210 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 6 (n=46,48,47,48,49,70) | 23 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 7 (n=48,47,46,49,50,71) | 21 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 12 (n=44,46,46,46,50,72) | 14 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 12 (n=45,45,45,43,46,69) | 75 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 12 (n=45,47,45,46,50,70) | 47 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 3 (n=49,47,46,48,50,71) | 45 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 3 (n=49,46,47,48,50,72) | 166 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 1 (n=48,48,47,49,50,70) | 107 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 6 (n=48,48,48,48,49,72) | 84 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. Y - month 1 (n=48,48,48,49,49,73) | 92 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. C - month 1 (n=48,48,48,48,50,71) | 75 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 6 (n=46,46,48,44,49,69) | 20 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. A - month 12 (n=43,44,45,46,50,71) | 14 Titers |
| 1ACWY | GMT for N Meningitidis Serogroups A, C, W and Y at Month 0 Through Month 12 Following Vaccination at Month 0, Month 2 With One of Four MenABCWY Formulations, rMenB, or MenACWY/Placebo | Ser. W - month 6 (n=44,47,45,45,43,69) | 117 Titers |
Secondary
Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination
Solicited local and systemic AEs were collected daily for 7 days (day 1 through day 7) after vaccination. One subject initially randomized to group 3ABCWYqOMV and supposed to receive rMenB+1/4OMV+ACWY as the third vaccination, actually received Tdap as the third vaccination and was included in 2ABCWYqOMV group for the safety analysis.
Time frame: From Day 1 to Day 7 after vaccination
Population: Analysis was done on Safety Set (all subjects in the exposed set who provided post-vaccination solicited AE data).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 5 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 0 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 3 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 6 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 18 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 1 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 18 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 6 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 10 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 4 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 5 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 5 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 3 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 3 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 2 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 4 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 7 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 10 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 14 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 8 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 20 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 6 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 33 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 9 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 5 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 6 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 11 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 33 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 33 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 5 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 12 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 2 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 13 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 23 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 14 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 4 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 2 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 3 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 0 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 7 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 0 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 2 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 11 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 18 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 3 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 6 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 15 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 9 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 9 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 5 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 7 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 7 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 1 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 20 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 5 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 12 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 3 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 3 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 10 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 2 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 2 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 35 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 14 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 25 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 35 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 17 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 12 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 9 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 20 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 8 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 23 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 12 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 10 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 23 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 10 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 7 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 15 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 6 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 9 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 5 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 4 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 3 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 6 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 1 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 9 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 6 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 14 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 18 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 7 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 3 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 36 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 23 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 5 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 35 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 11 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 1 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 17 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 11 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 11 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 1 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 14 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 4 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 11 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 8 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 20 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 19 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 7 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 3 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 3 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 10 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 6 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 13 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 4 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 18 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 13 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 7 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 3 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 15 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 19 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 0 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 1 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 6 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 5 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 30 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 4 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 7 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 24 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 3 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 30 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 8 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 3 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 1 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 5 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 5 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 7 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 5 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 9 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 17 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 7 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 6 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 3 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 2 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 9 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 1 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 17 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 2 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 3 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 14 Number of Subjects |
| 3 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 2 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 1 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 38 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 13 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 18 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 14 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 5 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 2 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 8 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 14 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 21 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 36 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 5 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 34 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 4 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 13 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 10 Number of Subjects |
| 2 B | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Malaise | 13 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Rash | 2 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site erythema | 19 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Local AEs | 53 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Chills | 8 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Nausea | 6 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Headache | 27 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site pain | 52 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Swelling | 14 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Injection site induration | 18 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fatigue | 9 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any other indicators of reactogenicity | 11 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Fever (≥38°C) | 4 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Arthralgia | 9 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Any Solicited Systemic AEs | 43 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Myalgia | 32 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Vaccination | Stay home | 3 Number of Subjects |
Secondary
Number of Subjects Reporting Unsolicited Adverse Events After Vaccination
Unsolicited AEs were collected with onset from Day 1 through Day 7 After Vaccination. One subject initially randomized to group 3ABCWYqOMV and supposed to receive rMenB+1/4OMV+ACWY as the third vaccination, actually received Tdap as the third vaccination and was included in 2ABCWYqOMV group for the safety analysis.
Time frame: From Day 1 to Day 7 after vaccination
Population: Analysis was done on the Safety Set (all subjects in the exposed set who provided post-vaccination unsolicited AE data).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 1 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 3 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3ABCWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 6 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 3ABx2CWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 4 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 1 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 3ABCWY+OMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 2 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 4 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 2 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 1 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 3 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 1 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 3 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 1 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 1 Number of Subjects |
| 3ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 3 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 2 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 0 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 2ABCWYqOMV | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 1 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 3 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 2 Number of Subjects |
| 2 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 2 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 6 Number of Subjects |
| 2 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 3 Number of Subjects |
| 2 B | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related SAEs | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Serious AEs | 0 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | Any AEs | 6 Number of Subjects |
| 1ACWY | Number of Subjects Reporting Unsolicited Adverse Events After Vaccination | At least possibly related AEs | 3 Number of Subjects |
Secondary
Numbers of Subjects With Other Unsolicited AEs
Unsolicited AEs were collected from Day 8 After vaccination Through Study Termination. One subject initially randomized to group 3ABCWYqOMV and supposed to receive rMenB+1/4OMV+ACWY as the third vaccination, actually received Tdap as the third vaccination and was included in 2ABCWYqOMV group for the safety analysis.
Time frame: Day 8 After vaccination Through Study Termination, up to 6 months
Population: Analysis was done on the Safety Set (all subjects in the exposed set who provided post-vaccination unsolicited AE data).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 5 Number of Subjects |
| 3ABCWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 3ABCWY | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 3ABCWY | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 3ABx2CWY | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 3ABx2CWY | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 7 Number of Subjects |
| 3ABx2CWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 3ABx2CWY | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 3ABx2CWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWY+OMV | Numbers of Subjects With Other Unsolicited AEs | SAEs | 1 Number of Subjects |
| 3ABCWY+OMV | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 4 Number of Subjects |
| 3ABCWY+OMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWY+OMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 3ABCWY+OMV | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 10 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | SAEs | 1 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 6 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 7 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 2 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 3ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 2ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 2ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | SAEs | 1 Number of Subjects |
| 2ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 2ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 2ABCWYqOMV | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 5 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 3 B | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 4 Number of Subjects |
| 2 B | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
| 2 B | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 14 Number of Subjects |
| 2 B | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 2 B | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 0 Number of Subjects |
| 2 B | Numbers of Subjects With Other Unsolicited AEs | SAEs | 1 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | Medically attended AEs | 15 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | AEs leading to Withdrawal | 0 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related AEs | 1 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | SAEs | 0 Number of Subjects |
| 1ACWY | Numbers of Subjects With Other Unsolicited AEs | At least possibly related SAEs | 0 Number of Subjects |
Secondary
Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as the percentage of subjects with 4-fold Increase in human serum bactericidal assay (hSBA) titers and associated 95% CI, Against Serogroup B Test Strains at One Month After Third Vaccination (month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Time frame: At month 7
Population: Analysis was done by MITT month 7 Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 80 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 80 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 4 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 56 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 36 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 88 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 67 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 54 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 80 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 88 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 17 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 23 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 83 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 60 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 65 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 61 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 83 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 83 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 52 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 76 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 44 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 79 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 44 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 88 Percentages of subjects |
| 3 B | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 73 Percentages of subjects |
| 3 B | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 29 Percentages of subjects |
| 3 B | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 57 Percentages of subjects |
| 3 B | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 17 Percentages of subjects |
| 3 B | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 50 Percentages of subjects |
| 3 B | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 90 Percentages of subjects |
| 1ACWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M14459 (fHBP) (n=25,24,23,25,22,71) | 1 Percentages of subjects |
| 1ACWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | NZ98/254 (PorA) (n=25,24,23,25,23,72) | 1 Percentages of subjects |
| 1ACWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M07-0241084 (NHBA) (n=25,22,20,25,21,69) | 0 Percentages of subjects |
| 1ACWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | M01-0240364 (NadA) (n=24,20,23,24,21,69) | 0 Percentages of subjects |
| 1ACWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | 5/99 (NadA) (n=25,24,23,25,23,72) | 3 Percentages of subjects |
| 1ACWY | Percentages of Subjects With 4-fold Increase in hSBA Titers Against Serogroup B Test Strains at One Month After Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | H44/76 (fHbp) (n=25,24,24,24,22,72) | 0 Percentages of subjects |
Secondary
Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo
Antibody response was measured as the percentage of subjects with seroresponse Against N meningitidis Serogroups A, C, W and Y, after pre and post vaccination at month 6 and after the third vaccination (month 7) with One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo. Seroresponse to N meningitidis serogroups A, C, W and Y is defined as: For subjects with a prevaccination hSBA \<1:4, a postvaccination hSBA ≥1:8;For subjects with a prevaccination hSBA ≥1:4, an increase in hSBA titer of at least four times the prevaccination titer.
Time frame: At month 7
Population: Analysis was done by MITT month 7 Set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 3ABCWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 59 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 48 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 35 Percentages of subjects |
| 3ABCWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 29 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 38 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 54 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 67 Percentages of subjects |
| 3ABx2CWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 38 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 43 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 48 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 59 Percentages of subjects |
| 3ABCWY+OMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 67 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 72 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 32 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 67 Percentages of subjects |
| 3ABCWYqOMV | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 58 Percentages of subjects |
| 3 B | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 60 Percentages of subjects |
| 3 B | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 5 Percentages of subjects |
| 3 B | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 60 Percentages of subjects |
| 3 B | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 82 Percentages of subjects |
| 1ACWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. C (n=21,24,22,24,20,70) | 0 Percentages of subjects |
| 1ACWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. W (n=23,24,21,24,20,69) | 3 Percentages of subjects |
| 1ACWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. Y (n=24,24,23,25,22,71) | 0 Percentages of subjects |
| 1ACWY | Percentages of Subjects With Seroresponse Against N Meningitidis Serogroups A, C, W and Y at 1 Month After the Third Vaccination With One of Four MenABCWY Formulations, rMenB or MenACWY/Placebo | Ser. A (n=22,24,21,25,22,68) | 3 Percentages of subjects |